# Acrivon Therapeutics, Inc.: Form 8-K, filed Mar 2, 2026

- Company: [Acrivon Therapeutics, Inc.](/companies/acrv.md) (CIK 1781174)
- Form: 8-K
- Filed: 2026-03-02
- Accepted by EDGAR: Mar 2, 2026, 16:30 ET
- Period: 2026-02-25
- Accession: 0001193125-26-085516
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/d111455d8k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/

## Items reported

- Item 1.02: Termination of a material agreement

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1781174/000119312526085516/d111455d8k.htm

Filed Mar 2, 2026.
Source: SEC EDGAR, the filing index for accession 0001193125-26-085516. Last ingested by Listed: Nov 11, 2026, 02:42 ET. No prices; not investment advice.
